Lung-MAP Study: This study is for adults with non-small cell lung cancer (NSCLC) that has been treated before. NSCLC is a type of lung cancer. The study aims to find the best treatments for patients based on specific traits, called biomarkers, of their cancer. Biomarkers are like unique markers in cancer cells that can help doctors decide which treatment might work best.

Eligibility: To join, you need to have Stage IV or recurrent NSCLC and have previously had certain treatments. You will need to provide a tumor sample and blood for testing. If you have specific gene mutations, you may not be eligible unless you’ve already tried standard therapies.

• Study Length: You'll be in the study as long as your treatment shows benefits.
• Visits Needed: Regular visits for treatment and monitoring are required.
• Risks and Benefits: You may benefit from new therapies but there might be risks or side effects.

You'll need to agree to let researchers keep leftover samples for future studies. Participation in additional surveys and studies is optional but could help with further research.